CN104547525A - Drug composition for NSCLC (Non Small Cell Lung Cancer) prevention and preparation method thereof - Google Patents
Drug composition for NSCLC (Non Small Cell Lung Cancer) prevention and preparation method thereof Download PDFInfo
- Publication number
- CN104547525A CN104547525A CN201410851720.9A CN201410851720A CN104547525A CN 104547525 A CN104547525 A CN 104547525A CN 201410851720 A CN201410851720 A CN 201410851720A CN 104547525 A CN104547525 A CN 104547525A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- add
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 45
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 14
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000002994 raw material Substances 0.000 claims abstract description 28
- 210000000582 semen Anatomy 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 239000008194 pharmaceutical composition Substances 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000012567 medical material Substances 0.000 claims description 28
- 239000006228 supernatant Substances 0.000 claims description 27
- 241000756943 Codonopsis Species 0.000 claims description 24
- 241000190633 Cordyceps Species 0.000 claims description 24
- 241000237903 Hirudo Species 0.000 claims description 24
- 239000009636 Huang Qi Substances 0.000 claims description 24
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 24
- 241000180649 Panax notoginseng Species 0.000 claims description 24
- 241000131808 Scolopendra Species 0.000 claims description 24
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 18
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 238000002386 leaching Methods 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 238000001291 vacuum drying Methods 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 235000008504 concentrate Nutrition 0.000 claims description 3
- -1 dry Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000003560 cancer drug Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 26
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 28
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 22
- 210000004072 lung Anatomy 0.000 description 21
- 206010011224 Cough Diseases 0.000 description 17
- 241000209020 Cornus Species 0.000 description 16
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 239000003172 expectorant agent Substances 0.000 description 7
- 230000003419 expectorant effect Effects 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004043 pneumocyte Anatomy 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 235000003840 Amygdalus nana Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 235000011432 Prunus Nutrition 0.000 description 3
- 241000220299 Prunus Species 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical group O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000014774 prunus Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013952 Dysphonia Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000010473 Hoarseness Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 235000010864 Armeniaca mandshurica Nutrition 0.000 description 1
- 244000147617 Armeniaca mandshurica Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241001092070 Eriobotrya Species 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 206010065873 Pulmonary fistula Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Insects & Arthropods (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A drug composition for NSCLC (Non Small Cell Lung Cancer) prevention comprises the following raw materials: astragalus membranaceus, radix pseudostellariae, radix ophiopogonis, schisandra chinensis, cordyceps sinensis, codonopsis pilosula, bulbus fritillariae cirrhosae, semen armeniacae amarae, folium eriobotryae, houttuynia cordata, angelica sinensis, pseudo-ginseng, cornua cervi pantotrichum, leech, oldenlandia diffusa, selfheal, sculellaria barbata, calculus bovis and centipede. The drug composition achieves medication safety, has no toxic or side effects, has excellent effect, can be used for effectively solving the problem of poor treatment effect of NSCLC, improves the life quality of patients suffering from the middle and advanced stage NSCLC, and prolongs the lifetime of the patients.
Description
Technical field
The invention belongs to medical art, relate to a kind of Chinese medicine composition, be specifically related to pharmaceutical composition of a kind of anti-nonsmall-cell lung cancer and preparation method thereof.
Background technology
Pulmonary carcinoma is clinical common malignant tumor, because of invisible, aggressive and the transitivity of growth of tumour cell, clinical medical time most nonsmall-cell lung cancer (english abbreviation: NSCLC) patient belonged to for III, IV phase and lost surgical engine meeting, chemicotherapy becomes main treatment means.The drawbacks such as right chemicotherapy exists damage human normal function, uncertain therapeutic efficacy is determined, or cause the undue treatment of tumor, affect the life quality of patient all to some extent.From treatment at present, because the grade malignancy of pulmonary carcinoma is high, biological characteristics is complicated, and simple western medical treatment clinical efficacy is dissatisfied.Numerous scholar reports in succession in recent years, there is the comprehensive therapeutic plan that Chinese medicine participates in, tool has clear improvement, and clinical symptoms, raising patients ' life quality, attenuation synergistic, antitumor relapse and metastasis etc. are many-sided to be acted on, all being better than the treatment of simple western medicine to recent, the late result of pulmonary carcinoma, is the safe and effective auxiliary treatment medication of tumor patient.Chinese medicine by determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, carries out Mutiple Targets, manifold effect and individualized treatment to pulmonary carcinoma, the likely farthest Tumor suppression development of combination of Chinese and Western medicine Comprehensive Treatment, improves life in patients and extending life.
Pulmonary carcinoma is a kind of multifactor coefficient disease, and various environmental factors such as smoking, kitchen fume, inherited genetic factors etc. can cause the generation of pulmonary carcinoma.Smoking is approved by a large amount of institute as the most important risk factor of pulmonary carcinoma.And the evidence achieved on many biological mechanisms.Indoor cooking fume is also approved by most scholar as Risk Factors of Lung Cancers, particularly to female lung cancer research aspect.Current modern medicine there is no effective therapeutic scheme.People attempt the cure rate being improved NSCLC by Comprehensive Treatment for many years, at present the treatment of this disease are adopted mostly to the complex treatment measure of the associating Chinese medicines such as operation, radiotherapy, chemotherapy, immunity, targeted therapy.Operation, radiotherapy, chemotherapy are the Main Means of Modern medical therapy malignant tumor, although the treatment of these invasives in removing, reduce in tumor there is certain effect, also there is the drawbacks such as damage human normal function, uncertain therapeutic efficacy be fixed over the course for the treatment of.Traditional medicine is thought: in pulmonary carcinoma forming process, and expectorant is important pathological product, is also one of key factor of pulmonary carcinoma generation.Expectorant is on the basis of human righteousness's weakness, and visceral dysfunction is formed.Function obstacle, ascending, descending, exiting and entering is not normal, can make inability of body fluid to function, gathers and forms expectorant.And expectorant is as new paathogenic factor, increased the weight of the not normal of function, so that ascending, descending, exiting and entering is not normal, qi-blood disharmony, qi depression to blood stasis, mental disorder is handed over and is fought, phlegm and blood stasis, and channels is obstructed, raw in lump, pulmonary carcinoma.Pulmonary carcinosis is because healthy energy is nothing more than deficient and heresy poison inner product two aspects, and expectorant is important pathological product.Therefore use with holding water Apophlegmatisant be medium and advanced lung cancer treatment in key one ring.TCM on Tumor has the history of several thousand, for the treatment of tumor have accumulated rich experience.The traditional Chinese medical science thinks that people is organic whole, and malignant tumor is the topical manifestations of general disease, is the disease of simulataneous insufficiency and excessive, Chinese medicine is not only effectively alone, and can apply with operation, radiotherapy, chemotherapy combined, produces cooperative compensating effectiveness, to strengthen therapeutic effect, alleviate untoward reaction.
The complicated clinical manifestation of pulmonary carcinoma, comprises symptom and Pulmonary hypofuntion that former block of swelling causes.The modal lump shadow having the symptoms such as cough, spitting of blood, chest pain, heating and the imaging examination such as CT, x-ray; The indirect performance wherein caused by airway obstruction should arouse attention; Finally making a definite diagnosis also must pathological diagnosis.The histological type of pulmonary carcinoma is divided into two large classes: small cell lung cancer and nonsmall-cell lung cancer.Small cell lung cancer (SCLC) accounts for 20% ~ 25%, and within more than 50 years old, male is common, and the case of about 70% is perihiar lump, and for breaking up poor neuroendocrine tumor, rapidly, easily extensively transfer, responsive to radiotherapy chemotherapy in growth.Nonsmall-cell lung cancer (NSCLC) accounts for 75% ~ 80%, comprises squamous cell carcinoma, adenocarcinoma and large cell carcinoma.Squamous cell carcinoma morbidity is many more than 50 years old, and M-F is 10:1, type centered by about 2/3; The ratio of adenocarcinoma sickness rate men and women is 2:1, common with peripheral; Large cell carcinoma high malignancy, is apt to occur in more than 60 years old male, and most of symptom affects relevant with tumor by local, and gross tumor volume is comparatively large, central common necrosis.Lung cancer metastasis approach has direct extension, lymph metastasis, hematogenous metastasis.The M & M of pulmonary carcinoma is high, has been middle and advanced stage when most of pulmonary carcinoma is made a definite diagnosis, and 5 years total survival rates, about 10%, are one of topmost fatal diseases.The life security of patient in serious threat, though the existing multi-medicament having treatment nonsmall-cell lung cancer, but for various reasons, its use is also unsatisfactory, and Chinese medicine has affluent resources and the unique distinction for the treatment of difficult miscellaneous diseases, therefore, treatment by Chinese herbs nonsmall-cell lung cancer how is utilized to be the technical problem needing solution at present badly.
Summary of the invention
The present invention is directed to the defect existed in prior art, pharmaceutical composition of a kind of anti-nonsmall-cell lung cancer and preparation method thereof is provided, this pharmaceutical composition drug safety, have no side effect, effective, can efficient solution small cell lung cancer poor effect by no means, improve the life quality of Patients with Advanced Non-small Cell Lung Cancer, extend its life-span.
Above-mentioned purpose of the present invention is realized by following technical proposals:
A pharmaceutical composition for anti-nonsmall-cell lung cancer, the crude drug of described pharmaceutical composition is made up of the Radix Astragali, Radix Pseudostellariae, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Cordyceps, Radix Codonopsis, Bulbus Fritillariae Cirrhosae, Semen Armeniacae Amarum, Folium Eriobotryae, Herba Houttuyniae, Radix Angelicae Sinensis, Radix Notoginseng, Cornu Cervi Pantotrichum, Hirudo, Herba Hedyotidis Diffusae, Spica Prunellae, Herba Scutellariae Barbatae, Calculus Bovis and Scolopendra.
Further, make described pharmaceutical composition raw material composition and parts by weight be: Radix Astragali 8-13 part, Radix Pseudostellariae 13-20 part, Radix Ophiopogonis 17-30 part; Fructus Schisandrae Chinensis 14-27 part, Cordyceps 17-23 part, Radix Codonopsis 5-11 part, Bulbus Fritillariae Cirrhosae 13-19 part; Semen Armeniacae Amarum 6-12 part, Folium Eriobotryae 3-9 part, Herba Houttuyniae 11-16 part; Radix Angelicae Sinensis 14-25 part, Radix Notoginseng 8-18 part, Cornu Cervi Pantotrichum 19-30 part; Hirudo 18-32 part, Herba Hedyotidis Diffusae 13-24 part, Spica Prunellae 4-9 part; Herba Scutellariae Barbatae 9-15 part, Calculus Bovis 8-12 part, Scolopendra 7-12 part.
Further, raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 10 parts, Radix Pseudostellariae 13 parts, Radix Ophiopogonis 17 parts; Fructus Schisandrae Chinensis 20 parts, Cordyceps 21 parts, Radix Codonopsis 10 parts, Bulbus Fritillariae Cirrhosae 15 parts; Semen Armeniacae Amarum 7 parts, Folium Eriobotryae 4 parts, Herba Houttuyniae 13 parts; Radix Angelicae Sinensis 19 parts, Radix Notoginseng 11 parts, 22 parts, Cornu Cervi Pantotrichum; Hirudo 27 parts, Herba Hedyotidis Diffusae 18 parts, Spica Prunellae 9 parts; Herba Scutellariae Barbatae 15 parts, Calculus Bovis 12 parts, Scolopendra 11 parts.
Further, raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 13 parts, Radix Pseudostellariae 17 parts, Radix Ophiopogonis 30 parts; Fructus Schisandrae Chinensis 14 parts, Cordyceps 23 parts, Radix Codonopsis 6 parts, Bulbus Fritillariae Cirrhosae 13 parts; Semen Armeniacae Amarum 6 parts, Folium Eriobotryae 9 parts, Herba Houttuyniae 11 parts; Radix Angelicae Sinensis 15 parts, Radix Notoginseng 8 parts, 19 parts, Cornu Cervi Pantotrichum; Hirudo 30 parts, Herba Hedyotidis Diffusae 13 parts, Spica Prunellae 5 parts; Herba Scutellariae Barbatae 9 parts, Calculus Bovis 10 parts, Scolopendra 12 parts.
Further, raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 8 parts, Radix Pseudostellariae 20 parts, Radix Ophiopogonis 19 parts; Fructus Schisandrae Chinensis 27 parts, Cordyceps 17 parts, Radix Codonopsis 5 parts, Bulbus Fritillariae Cirrhosae 19 parts; Semen Armeniacae Amarum 10 parts, Folium Eriobotryae 6 parts, Herba Houttuyniae 15 parts; Radix Angelicae Sinensis 14 parts, Radix Notoginseng 18 parts, 27 parts, Cornu Cervi Pantotrichum; Hirudo 32 parts, Herba Hedyotidis Diffusae 15 parts, Spica Prunellae 4 parts; Herba Scutellariae Barbatae 12 parts, Calculus Bovis 8 parts, Scolopendra 7 parts.
Further, raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 9 parts, Radix Pseudostellariae 15 parts, Radix Ophiopogonis 24 parts; Fructus Schisandrae Chinensis 16 parts, Cordyceps 19 parts, Radix Codonopsis 8 parts, Bulbus Fritillariae Cirrhosae 16 parts; Semen Armeniacae Amarum 12 parts, Folium Eriobotryae 8 parts, Herba Houttuyniae 16 parts; Radix Angelicae Sinensis 25 parts, Radix Notoginseng 15 parts, 30 parts, Cornu Cervi Pantotrichum; Hirudo 18 parts, Herba Hedyotidis Diffusae 20 parts, Spica Prunellae 7 parts; Herba Scutellariae Barbatae 14 parts, Calculus Bovis 9 parts, Scolopendra 9 parts.
Further, raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 11 parts, Radix Pseudostellariae 18 parts, Radix Ophiopogonis 28 parts; Fructus Schisandrae Chinensis 23 parts, Cordyceps 18 parts, Radix Codonopsis 9 parts, Bulbus Fritillariae Cirrhosae 17 parts; Semen Armeniacae Amarum 8 parts, Folium Eriobotryae 3 parts, Herba Houttuyniae 12 parts; Radix Angelicae Sinensis 23 parts, Radix Notoginseng 11 parts, 22 parts, Cornu Cervi Pantotrichum; Hirudo 20 parts, Herba Hedyotidis Diffusae 24 parts, Spica Prunellae 9 parts; Herba Scutellariae Barbatae 10 parts, Calculus Bovis 11 parts, Scolopendra 8 parts.
Further, raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 7 parts, Radix Pseudostellariae 16 parts, Radix Ophiopogonis 21 parts; Fructus Schisandrae Chinensis 26 parts, Cordyceps 22 parts, Radix Codonopsis 5-11 part, Bulbus Fritillariae Cirrhosae 13 parts; Semen Armeniacae Amarum 10 parts, Folium Eriobotryae 5 parts, Herba Houttuyniae 11 parts; Radix Angelicae Sinensis 20 parts, Radix Notoginseng 13 parts, 25 parts, Cornu Cervi Pantotrichum; Hirudo 25 parts, Herba Hedyotidis Diffusae 22 parts, Spica Prunellae 6 parts; Herba Scutellariae Barbatae 11 parts, Calculus Bovis 8 parts, Scolopendra 10 parts.
The invention still further relates to a kind of preparation method of pharmaceutical composition of described anti-nonsmall-cell lung cancer, comprise the steps:
---get each medical material by needed raw material composition and parts by weight, add the 6-8 water doubly of medical material gross weight, soak 30-60 minute, decoct 2 times, each 2-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 75% (v/v), leave standstill 30-40 hour, get supernatant, reclaim ethanol and concentrate, add water to 1000ml, stir evenly, subpackage, flowing steam sterilization 35min, obtained mixture; Or
---get each medical material by needed raw material composition and parts by weight, add the water of 10 times of medical material gross weight, soak 60-100 minute, decoct 2 times, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is the testing result under 60-65 degree Celsius, adding ethanol to alcohol content is 85% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting obtains tablet; Or
---get each medical material by needed raw material composition and parts by weight, add the 8-10 water doubly of medical material gross weight, soak 45-60 minute, decoct 4 times, each 1.5-2 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is the testing result under 60-65 degree Celsius, adding ethanol to alcohol content is 90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated obtained capsule product; Or
---get each medical material by needed raw material composition and parts by weight, add 6-10 times of water gaging, decoct 2-3 hour, leach medicine juice; Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice; Merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount ethanol, stir precipitates overnight; Get supernatant, be concentrated into thick extractum; Add pharmaceutic adjuvant, vacuum drying, pulverize and granulate, dry, granulate, obtains 20g granule, subpackage 10g/ bag, obtained granule; Or
---get each medical material by needed raw material composition and parts by weight, add 6-9 times of water gaging, decoct 2-3 hour, leach medicine juice; Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice; Merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount ethanol, stir precipitates overnight; Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids (conventionally selecting pharmaceutic adjuvant), make oral liquid; Or
---get each medical material by needed raw material composition and parts by weight, add 6-9 times of water gaging, decoct 2-3 hour, leach medicine juice; Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice; Merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount ethanol, stir precipitates overnight; Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, make syrup.
The invention still further relates to the application of described pharmaceutical composition in anti-non-small cell lung cancer drug.
The pharmaceutical composition of anti-nonsmall-cell lung cancer provided by the present invention, it for raw material, gives full play to the property of medicine of each component with common Chinese herbal medicine:
The Radix Astragali: sweet in the mouth, tepor.Return lung, spleen, liver, kidney channel.There is the effects such as invigorating QI to consolidate the body surface resistance, diuretic detumescent, expelling pus and toxin by strengthening QI, granulation promoting.Have enhancing human body immunity function, protect the liver, diuresis, defying age, anti-stress, blood pressure lowering and antibacterial action more widely.
Radix Pseudostellariae: sweet, micro-hardship, tepor.Qi-restoratives medicine, Qi-tonifying drug.Effect: mend strengthening spleen and lung, supplementing QI for promoting the production of body fluid.Control cough due to deficiency of the lung, insufficiency of the spleen lack of appetite, cardiopalmus, palpitation with a distress feeling, edema, quenches one's thirst, metal fatigue.For deficiency-weakness of spleen-QI, deficiency of stomach-Yin, lack of appetite body is tired, thirsty dry tongue; Deficiency of the lung cough caused by dryness, dry pharynx expectorant glues; Deficiency of both vital energy and Yin, palpitation and insomnia.
Radix Ophiopogonis, sweet, micro-hardship, is slightly cold.GUIXIN, lung, stomach warp.YIN nourishing and the production of body fluid promoting, lung moistening clears away heart-fire.For dryness of the lung dry cough.Chronic consumptive disease is coughed, and Tianjin wound is thirsty, vexed insomnia, and interior-heat is quenched one's thirst, dryness of the intestine constipation; Pharyngeal diphtheria.
Fructus Schisandrae Chinensis: have convergence astringent or styptic treatment for spontaneous sweating, supplementing QI for promoting the production of body fluid, effect of kidney calming, is usually used in chronic cough dyspnea due to deficiency, emission, enuresis frequent micturition, incessant chronic diarrhea, spontaneous perspiration, night sweat, Tianjin wound is thirsty, and deficient pulse of losing heart, interior-heat is quenched one's thirst, palpitation and insomnia.
Cordyceps: there is the effects such as tonify deficiency kidney, beneficial vital essence, soreness of waist and knee joint can be treated, pulmonary fistula, chronic cough consumptive disease are coughed, pass out semen, sexual impotence, premature ejaculation, the various disease conditions such as menoxenia.
Radix Codonopsis: there is invigorating the spleen and replenishing QI, effect of spleen invigorating lung benefiting.For deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency is coughed, and interior-heat is quenched one's thirst.
Bulbus Fritillariae Cirrhosae: cool in nature, Gan Ping.Enter lung, stomach warp.Nourishing the lung to arrest cough, resolving phlegm and relieving asthma, removing heat-phlegm.
Semen Armeniacae Amarum is the dry mature seed of rosaceous plant Prunus armeniaca L.var.ansu Maxim. Prun.us armemaca L.var.ansuMaxim., Siberia Fructus Pruni Prunus sibiricaL., prunus mandshuricaKoehne Prunusmandshurica (Maxim.) Koehne or Fructus Pruni Prunus armenz.acaL..To gather summer mature fruit, in removing fruit and nucleocapsid, take out seed, dry.Nature and flavor are bitter, tepor; Slightly poisonous.Return lung, large intestine channel.Cure mainly sending down the abnormal ascending QI relieving cough and asthma, loosening bowel to relieve constipation.For cough and asthma, fullness in the chest abundant expectoration, dryness of the intestine constipation.
Folium Eriobotryae is the dried leaves of rosaceous plant Folium Eriobotryae Eriobotrya jaPon.ica (Thunb.) I, indl..The whole year all can gather, shine to seven, most probably thousand time, be bundled into wisp, then dry.Nature and flavor are bitter, are slightly cold.Attach to the lung and stomach meridians.Clearing away lung-heat to relieve cough, stopping nausea and vomiting by lowering the adverse flow of QI.For cough due to lung-heat, QI rising in reverse order dyspnea with rapid respiration, gastric heat vomiting, dysphoria with smothery sensation is thirsty.
Herba Houttuyniae: cold nature, bitter in the mouth.Return lung meridian, bladder, large intestine channel.Heat-clearing and toxic substances removing, removing pus and relieving carbuncle, inducing diuresis for treating stranguria syndrome.Cure mainly: lung abscess vomiting pus; Expectorant dyspnea of heat type is coughed; Larynx; Hematodiarrhoea; Carbuncle sore tumefacting virus;
Radix Angelicae Sinensis: having enriches blood invigorates blood circulation, effect of menstruction regulating and pain relieving, loosening bowel to relieve constipation, for blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.
Radix Notoginseng: dissipating blood stasis stops blooding, subduing swelling and relieving pain.For various inside and outside hemorrhage, breast ventral spine pain, tumbling and swelling.
Cornu Cervi Pantotrichum: have kidney-Yang invigorating, fills blood, beneficial marrow, effect of bone and muscle strengthening.For controlling asthenia weakness and emaciation, spirit is tired weary, dizzy, deaf, and order is dark, soreness of waist and knee joint, sexual impotence, spermatorrhea; Deficiency-cold of uterus, metrorrhagia, leukorrhagia.
Hirudo: salty in the mouth, hardship, property is put down.Return Liver Channel.The benefaction of gas raw meat, enters blood broken loose.
Herba Hedyotidis Diffusae: bitter in the mouth, sweet, cold in nature, enters the heart, liver, spleen, large intestine channel, has heat-clearing and toxic substances removing, the effect of promoting diuresis to eliminate damp pathogen, for dyspnea and cough due to lung-heat, laryngopharynx swelling and pain, acute appendicitis, furuncle and phyma skin infection, venom, the puckery pain of pyretic stranguria, edema, dysentery, enteritis, jaundice due to damp-heat, the cards such as cancerous protuberance, often utilize Herba Hedyotidis Diffusae anticancer, and it has certain radiation resistance.
Spica Prunellae: bitter in the mouth; Pungent; Cold in nature.Return liver; Gallbladder meridian.Liver heat removing and eyesight improving; Powder detoxifcation.Cure mainly corneal nebula photophobia; Ophthalmalgia; Have a headache dizzy; Tinnitus; Scrofula; Goiter; Acute mastitis; Mumps; Carbuncle furuncle and phyma poison; Acute, chronic hepatitis; Hypertension." the southern regions of the Yunnan Province book on Chinese herbal medicine " carries: " liver-wind of dispelling, network of passing through.Control facial hemiparalysis, row irritability, opens stagnation of liver-QI, only bones and muscles pain, ophthal malgia, loose scrofula, whole body tuberculosis." modern medicine study confirmation, Spica Prunellae has significant blood pressure lowering and antibacterial action.
Herba Scutellariae Barbatae: cool in nature, mildly bitter flavor.Return lung, liver, kidney channel.Tool heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, the function such as anticancer.For furuncle swelling toxin, laryngopharynx swelling and pain, venom, falls and flutters the pain of injury, edema, jaundice.
Calculus Bovis: have clear away heart-fire, eliminating phlegm, have one's ideas straightened out, cool liver, endogenous wind stopping, removing toxic substances effect, for calentura coma, middle wind-phlegm fan, infantile convulsion twitch, epilepsy is gone mad, laryngopharynx swelling and pain, aphtha of the mouth and tongue, carbuncle furuncle.
Scolopendra: there is anticancer, the relieving spasm by calming endogenous wind of relieving internal heat, move back effect that inflammation controls skin ulcer.
The present invention is according to theory of Chinese medical science monarch prescription, there is invigorating QI to consolidate the body surface resistance, the Radix Astragali of supplementing QI for promoting the production of body fluid effect, Radix Pseudostellariae, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Cordyceps, Radix Codonopsis is monarch drug, there is nourishing the lung to arrest cough, the Bulbus Fritillariae Cirrhosae of resolving phlegm and relieving asthma effect, Semen Armeniacae Amarum, Folium Eriobotryae, Herba Houttuyniae is ministerial drug, having enriches blood invigorates blood circulation, benefit marrow, the Radix Angelicae Sinensis of bone and muscle strengthening effect, Radix Notoginseng, Hirudo and Cornu Cervi Pantotrichum are adjuvant drug, there is the Herba Hedyotidis Diffusae of antipyretic and antidote functions, Spica Prunellae, Herba Scutellariae Barbatae, Calculus Bovis, Scolopendra is for making medicine, each medicine synergism in side, play benefiting QI for strengthening the superficies altogether, nourishing the lung to arrest cough, resolving phlegm and relieving asthma, blood circulation promoting and dispersing pathogen accumulation, effect of anti-inflammatory analgetic.
Beneficial effect: Chinese medicine composition of the present invention, by benefiting QI for strengthening the superficies, nourishing the lung to arrest cough, resolving phlegm and relieving asthma, blood circulation promoting and dispersing pathogen accumulation, anti-inflammatory analgetic effect, improves immunity, and suppress lung cancer cell growth and diffusion, significantly alleviate Lung Cancer Symptoms, determined curative effect, effective percentage is high.And this Chinese medicine composition drug safety, have no side effect, effective, can efficient solution small cell lung cancer poor effect by no means, improve the life quality of Patients with Advanced Non-small Cell Lung Cancer, extend its life-span.
Detailed description of the invention
For making the object of the embodiment of the present invention, technical scheme and advantage clearly, below in conjunction with embodiment, technical scheme of the present invention is clearly and completely described.Obviously, described embodiment is a part of the present invention, instead of whole embodiments.Based on described embodiments of the invention, the every other embodiment that those of ordinary skill in the art obtain under without the need to the prerequisite of creative work, all belongs to the scope of protection of the invention.Except as otherwise noted, the percent of the amount of alcohol in the present invention is percentage by volume, and v/v represents the volume ratio of solution.
Embodiment 1:
The pharmaceutical composition of a kind of anti-nonsmall-cell lung cancer of the present invention, gets following traditional Chinese medicine raw medicine: the Radix Astragali 10 grams, Radix Pseudostellariae 13 grams, Radix Ophiopogonis 17 grams; Fructus Schisandrae Chinensis 20 grams, Cordyceps 21 grams, Radix Codonopsis 10 grams, Bulbus Fritillariae Cirrhosae 15 grams; Semen Armeniacae Amarum 7 grams, Folium Eriobotryae 4 grams, Herba Houttuyniae 13 grams; Radix Angelicae Sinensis 19 grams, Radix Notoginseng 11 grams, 22 grams, Cornu Cervi Pantotrichum; Hirudo 27 grams, Herba Hedyotidis Diffusae 18 grams, Spica Prunellae 9 grams; Herba Scutellariae Barbatae 15 grams, Calculus Bovis 12 grams, Scolopendra 11 grams.
Embodiment 2:
The pharmaceutical composition of a kind of anti-nonsmall-cell lung cancer of the present invention, gets following traditional Chinese medicine raw medicine: the Radix Astragali 13 grams, Radix Pseudostellariae 17 grams, Radix Ophiopogonis 30 grams; Fructus Schisandrae Chinensis 14 grams, Cordyceps 23 grams, Radix Codonopsis 6 grams, Bulbus Fritillariae Cirrhosae 13 grams; Semen Armeniacae Amarum 6 grams, Folium Eriobotryae 9 grams, Herba Houttuyniae 11 grams; Radix Angelicae Sinensis 15 grams, Radix Notoginseng 8 grams, 19 grams, Cornu Cervi Pantotrichum; Hirudo 30 grams, Herba Hedyotidis Diffusae 13 grams, Spica Prunellae 5 grams; Herba Scutellariae Barbatae 9 grams, Calculus Bovis 10 grams, Scolopendra 12 grams.
Embodiment 3:
The pharmaceutical composition of a kind of anti-nonsmall-cell lung cancer of the present invention, gets following traditional Chinese medicine raw medicine: the Radix Astragali 8 grams, Radix Pseudostellariae 20 grams, Radix Ophiopogonis 19 grams; Fructus Schisandrae Chinensis 27 grams, Cordyceps 17 grams, Radix Codonopsis 5 grams, Bulbus Fritillariae Cirrhosae 19 grams; Semen Armeniacae Amarum 10 grams, Folium Eriobotryae 6 grams, Herba Houttuyniae 15 grams; Radix Angelicae Sinensis 14 grams, Radix Notoginseng 18 grams, 27 grams, Cornu Cervi Pantotrichum; Hirudo 32 grams, Herba Hedyotidis Diffusae 15 grams, Spica Prunellae 4 grams; Herba Scutellariae Barbatae 12 grams, Calculus Bovis 8 grams, Scolopendra 7 grams.
Embodiment 4:
The pharmaceutical composition of a kind of anti-nonsmall-cell lung cancer of the present invention, gets following traditional Chinese medicine raw medicine: the Radix Astragali 9 grams, Radix Pseudostellariae 15 grams, Radix Ophiopogonis 24 grams; Fructus Schisandrae Chinensis 16 grams, Cordyceps 19 grams, Radix Codonopsis 8 grams, Bulbus Fritillariae Cirrhosae 16 grams; Semen Armeniacae Amarum 12 grams, Folium Eriobotryae 8 grams, Herba Houttuyniae 16 grams; Radix Angelicae Sinensis 25 grams, Radix Notoginseng 15 grams, 30 grams, Cornu Cervi Pantotrichum; Hirudo 18 grams, Herba Hedyotidis Diffusae 20 grams, Spica Prunellae 7 grams; Herba Scutellariae Barbatae 14 grams, Calculus Bovis 9 grams, Scolopendra 9 grams.
Embodiment 5:
The pharmaceutical composition of a kind of anti-nonsmall-cell lung cancer of the present invention, gets following traditional Chinese medicine raw medicine: the Radix Astragali 11 grams, Radix Pseudostellariae 18 grams, Radix Ophiopogonis 28 grams; Fructus Schisandrae Chinensis 23 grams, Cordyceps 18 grams, Radix Codonopsis 9 grams, Bulbus Fritillariae Cirrhosae 17 grams; Semen Armeniacae Amarum 8 grams, Folium Eriobotryae 3 grams, Herba Houttuyniae 12 grams; Radix Angelicae Sinensis 23 grams, Radix Notoginseng 11 grams, 22 grams, Cornu Cervi Pantotrichum; Hirudo 20 grams, Herba Hedyotidis Diffusae 24 grams, Spica Prunellae 9 grams; Herba Scutellariae Barbatae 10 grams, Calculus Bovis 11 grams, Scolopendra 8 grams.
Embodiment 6
A pharmaceutical composition for anti-nonsmall-cell lung cancer, gets following traditional Chinese medicine raw medicine: the Radix Astragali 7 grams, Radix Pseudostellariae 16 grams, Radix Ophiopogonis 21 grams; Fructus Schisandrae Chinensis 26 grams, Cordyceps 22 grams, Radix Codonopsis 5-11 gram, Bulbus Fritillariae Cirrhosae 13 grams; Semen Armeniacae Amarum 10 grams, Folium Eriobotryae 5 grams, Herba Houttuyniae 11 grams; Radix Angelicae Sinensis 20 grams, Radix Notoginseng 13 grams, 25 grams, Cornu Cervi Pantotrichum; Hirudo 25 grams, Herba Hedyotidis Diffusae 22 grams, Spica Prunellae 6 grams; Herba Scutellariae Barbatae 11 grams, Calculus Bovis 8 grams, Scolopendra 10 grams.
The pharmaceutical composition of the described anti-nonsmall-cell lung cancer of embodiment 1-6 can be made into the form of mixture, tablet, syrup, oral liquid, capsule or granule, also can be prepared into the different pharmaceutical such as honeyed pill, drop pill version.
Wherein, the preparation method of mixture is:
Each medical material of components by weight percent in the described pharmaceutical composition that Example 1-6 is arbitrary, add the 6-8 water doubly of medical material gross weight, soak 30-60 minute, decoct 2 times, each 2-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 75% (v/v), leave standstill 30-40 hour, get supernatant, reclaim ethanol and concentrate, add water to 1000ml, stir evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
The preparation method of tablet is:
In the described pharmaceutical composition that Example 1-6 is arbitrary, each medical material of components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60-100 minute, decoct 2 times, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is the testing result under 60-65 degree Celsius, adding ethanol to alcohol content is 85% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
The preparation method of capsule is:
In the described pharmaceutical composition that Example 1-6 is arbitrary, each medical material of components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45-60 minute, decoct 4 times, each 1.5-2 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is the testing result under 60-65 degree Celsius, adding ethanol to alcohol content is 90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
The preparation method of granule is:
In the described pharmaceutical composition that Example 1-6 is arbitrary, each medical material of components by weight percent, adds 6-10 times of water gaging, decocts 2-3 hour, leaches medicine juice; Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice; Merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount ethanol, stir precipitates overnight; Get supernatant, be concentrated into thick extractum; Add pharmaceutic adjuvant (conventionally selecting pharmaceutic adjuvant), vacuum drying, pulverize and granulate, dry, granulate, obtains 20g granule, subpackage 10g/ bag.
The preparation method of oral liquid is:
In the described pharmaceutical composition that Example 1-6 is arbitrary, each medical material of components by weight percent, adds 6-9 times of water gaging, decocts 2-3 hour, leaches medicine juice; Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice; Merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount ethanol, stir precipitates overnight; Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids (conventionally selecting pharmaceutic adjuvant), make oral liquid.
The preparation method of syrup is:
In the described pharmaceutical composition that Example 1-6 is arbitrary, each medical material of components by weight percent, gets each medical material of above-mentioned components by weight percent, adds 6-9 times of water gaging, decocts 2-3 hour, leaches medicine juice; Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice; Merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount ethanol, stir precipitates overnight; Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids (conventionally selecting pharmaceutic adjuvant), make syrup.
Acute toxicity test:
Get mice 40,2 groups are divided at random: granule group takes granule prepared by the embodiment of the present invention 3, dose 0.37g/ml, and matched group takes distilled water by body weight, 0.5ml/10g body weight gastric infusion is pressed in fasting after 12 hours, three times on the one, to observation post administration 14 days, none was dead for mice, main organs no abnormality seen, also have no other obviously abnormal, within the 14th day, put to death and cut open inspection some animals, perusal main organs no abnormality seen.The maximum test medicine amount of mice is 44.8g/kg, suitable 180.99g crude drug/kg, is about 398.2 times that clinical people intends consumption.The toxic reaction of granule prepared by the embodiment of the present invention 3 is not observed under this dosage.
Six months long term toxicity tests: weigh weekly once during administration, every day claims appetite, without dead or moribund animals, result mice hair color is bright and clean, and behavioral activity, glandular secretion, breathing, feces character are all normal.Body weight inspection is pointed out, and this product heavy dose can slow down male mice body weight and increase.Routine blood test is pointed out, and this product long-term taking can improve leukocyte and erythrocyte, reticulocyte, hemoglobin, red cell volume etc.Blood biochemical is pointed out, and this product large dose oral administration 6 months individual animal can cause ALT to raise, and can recover after drug withdrawal.Pathologic finding is pointed out, to various internal organs without obvious drug-induced pathological change.
The impact that pharmaceutical composition of the present invention grows typeⅡ pneumocyte transplanted tumor in nude mice
The preparation of people's Pulmonary carcinoma nude mice Transplanted tumor model:
SPF level BALB/c-nu mice 60,8 week age, weight l8g-22g.Take the logarithm trophophase lung cancer cell types cell, adjusting A549 cell concentration with aseptic PBS is 3.3 × 10
7/ mL, at BALB/c-nu mouse back subcutaneous vaccination A549 cell 0.12ml, treats that subcutaneous transplantation tumor volume reaches 80mm
3during left and right (about 12d), model manufacturing success.
Grouping and administration:
Be divided into following 3 groups by tumor volume and mice with tumor body weight homeostatic principle, often organize 20:
Model control group: the normal saline of gavage equivalent 1 times/day, altogether administration 30 days;
Chinese drug-treated group: gavage gives mixture aqueous solution prepared by embodiment 3, and dosage is 55g crude drug/kg, early 8:00, afternoon, 16:00, was total to administration 30 days by 2 times/day;
Oxaliplatin group: lumbar injection 12mg/kg oxaliplatin, the next day administration 1 time, amount to 10 times.
During administration every 4 days with the most major diameter (L) of vernier caliper measurement transplanted tumor and most minor axis (w).After last administration 48h, mice is put to death in dislocation, and excision transplanted tumor, takes tumor weight.Tumor-like hyperplasia (%) IR=(1-experimental group tumor weight-average value/model control group tumor weight-average value) × 100%.What weighed by tumor relatively embodies the impact of medicine on the growth of typeⅡ pneumocyte nude mice suppression tumor.Data represent with mean ± standard deviation (x ± s), adopt SPSS15.0 software to carry out variance analysis.
Results and analysis:
The impact that table 1 pharmaceutical composition of the present invention grows typeⅡ pneumocyte transplanted tumor in nude mice
| Group | Tumor weight/mg | Average tumour inhibiting rate/% |
| Model control group | 394.60±61.32 | ------- |
| Oxaliplatin group | 207.13±74.3 * | 47.51 |
| Chinese drug-treated group | 178.81±55.92 ** | 54.69 |
Compare with model control group, * P < 0.05, * * P < 0.01.
Result of the test shows (see table 1): compared with model control group, each treatment group all has significant difference to the inhibitory action that typeⅡ pneumocyte transplanted tumor in nude mice grows, especially compared with model control group, pharmaceutical composition group of the present invention has pole significant difference (P < 0.01) in the inhibitory action grown typeⅡ pneumocyte transplanted tumor in nude mice, compared with chemotherapy oxaliplatin group, average tumour inhibiting rate increases, this illustrates that pharmaceutical composition of the present invention has extremely significant curative effect in treatment nonsmall-cell lung cancer, while the remarkable drug effect of acquisition, there is the low advantage of toxic and side effects, obtain unforeseeable technique effect.
Clinical trial:
In order to verify the effect of pharmaceutical composition of the present invention, in June ,-2013 in November, 2011, under the guidance of Shandong hospital oncology expert, the patients with advanced NSCLC that outpatient service place Stochastic choice 120 example is made a definite diagnosis through histopathologic examination, the capsule of all oral embodiment of the present invention 6 pharmaceutical composition, every day three times, each four, within three weeks, be a course for the treatment of, treat three courses for the treatment of altogether.Result: 120 routine patients all can evaluate, complete incidence graph (CR) 27 example, partial rcsponse (PR) 34 example; pathological changes stable (SD) 31 example; lesion growth (PD) 8 example, the recent effective percentage 61% of patient, meta progression of disease (TTP) 5.1 months; median survival interval 14.2 months, 1 year survival rate 77.1%.Main toxicity is few patients's hemoglobin reduction, thrombocytopenia and electrocardiographic abnormality, but all can tolerate.Conclusion: the embodiment of the present invention 6 medicine composite for curing advanced Non-small cell lung has good clinical efficacy, can improve the life quality of patient, extends life span, and toxicity is relatively lighter, and patient all can tolerate.
Simultaneously, in July ,-2013 in March, 2012, under the guidance of Shandong hospital oncology expert, outpatient service place has been randomly drawed 200 and has been diagnosed as patients with advanced NSCLC through histopathology and cytolgical examination, adopts random digits table stochastic averagina to be divided into treatment group and matched group.Wherein, treatment group 100 example, 36 ~ 71 years old age, average 52.5 years old; Matched group 100 example, age 34-73 year, average 53.4 years old.The two groups of data such as age, state of an illness there was no significant differences, have comparability.
Wherein treatment group takes the granule of the embodiment of the present invention 6 pharmaceutical composition, every day three times, each four bags, within three weeks, is a course for the treatment of, treats three courses for the treatment of altogether.Matched group adopts NP chemotherapy regimen, treats two courses for the treatment of (eight weeks).
Efficacy analysis result, effective 71 examples for the treatment of group, effective percentage 71%, effective 36 examples of chemotherapy group, effective percentage 36%, the visible embodiment of the present invention 6 pharmaceutical composition effective percentage is apparently higher than chemotherapy group, and at treatment nonsmall-cell lung cancer, (pyretic toxicity stops up lung to the embodiment of the present invention 6 pharmaceutical composition, phlegm and blood stasis, syndrome of blood stasis due to qi deficiency) there is good therapeutic effect aspect, effectively can improve clinical symptoms, improves immunologic function, extend patient's life-span, improve the life quality of patient.
Here is the sufferer that the daily clinic of inventor contacts and the model case contacted with outpatient service in Shandong hospital oncology expert cooperative process:
Case 1:
Zhao, man, 55 years old, coughs the several months at the beginning of patient 2012, and companion's hoarseness, feels sick, low grade fever night sweat, and Upper abdominal pain is uncomfortable, inappetence, the symptoms such as general fatigue, carries out CT and MRI inspection be diagnosed as pulmonary carcinoma to hospital.Tcm diagnosis is scorchingly hot stagnation type lump in the right hypochondrium.Take the capsule of the embodiment of the present invention 6 pharmaceutical composition, every day three times, each two, warm water is taken after mixing it with water after meal, within three weeks, is a course for the treatment of, and after treating three courses for the treatment of altogether, patient's cough, Upper abdominal pain, hoarseness symptom obviously alleviate, and appetite takes a turn for the better.
Case 2:
Money, female, 67 years old, people from Lixia District, Jinan City, within 2012, JIUYUE was gone to a doctor on the 10th, and patients symptomatic is uncomfortable in chest, out of breath, expectoration, and has lasting, fixing and violent chest pain, and lean body mass is weak.The inspection of row breast CT finds right lung space occupying lesion, the a large amount of hydrops in companion thoracic cavity, right side, takes the capsule of the embodiment of the present invention 1 pharmaceutical composition, every day three times, each two, warm water is taken after mixing it with water after meal, within three weeks, is a course for the treatment of, after treating four courses for the treatment of altogether, patient is uncomfortable in chest, asthma, expectoration symptom disappear completely, without hydrothorax, appetite increases, sleep quality improves, and the state of an illness is obviously controlled.
Last it is noted that above embodiment is only in order to illustrate technical scheme of the present invention, be not intended to limit; Although with reference to previous embodiment to invention has been detailed description, those of ordinary skill in the art is to be understood that: it still can be modified to the technical scheme described in foregoing embodiments, or carries out equivalent replacement to wherein portion of techniques feature; And these amendments or replacement, do not make the essence of appropriate technical solution depart from the scope of various embodiments of the present invention technical scheme.
Claims (10)
1. a pharmaceutical composition for anti-nonsmall-cell lung cancer, is characterized in that: the crude drug of described pharmaceutical composition is made up of the Radix Astragali, Radix Pseudostellariae, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Cordyceps, Radix Codonopsis, Bulbus Fritillariae Cirrhosae, Semen Armeniacae Amarum, Folium Eriobotryae, Herba Houttuyniae, Radix Angelicae Sinensis, Radix Notoginseng, Cornu Cervi Pantotrichum, Hirudo, Herba Hedyotidis Diffusae, Spica Prunellae, Herba Scutellariae Barbatae, Calculus Bovis and Scolopendra.
2. the pharmaceutical composition of anti-nonsmall-cell lung cancer according to claim 1, it is characterized in that: raw material composition and the parts by weight of making described pharmaceutical composition are: Radix Astragali 8-13 part, Radix Pseudostellariae 13-20 part, Radix Ophiopogonis 17-30 part, Fructus Schisandrae Chinensis 14-27 part, Cordyceps 17-23 part, Radix Codonopsis 5-11 part, Bulbus Fritillariae Cirrhosae 13-19 part, Semen Armeniacae Amarum 6-12 part, Folium Eriobotryae 3-9 part, Herba Houttuyniae 11-16 part, Radix Angelicae Sinensis 14-25 part, Radix Notoginseng 8-18 part, Cornu Cervi Pantotrichum 19-30 part, Hirudo 18-32 part, Herba Hedyotidis Diffusae 13-24 part, Spica Prunellae 4-9 part, Herba Scutellariae Barbatae 9-15 part, Calculus Bovis 8-12 part, Scolopendra 7-12 part.
3. the pharmaceutical composition of anti-nonsmall-cell lung cancer according to claim 1, is characterized in that: raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 10 parts, Radix Pseudostellariae 13 parts, Radix Ophiopogonis 17 parts; Fructus Schisandrae Chinensis 20 parts, Cordyceps 21 parts, Radix Codonopsis 10 parts, Bulbus Fritillariae Cirrhosae 15 parts; Semen Armeniacae Amarum 7 parts, Folium Eriobotryae 4 parts, Herba Houttuyniae 13 parts; Radix Angelicae Sinensis 19 parts, Radix Notoginseng 11 parts, 22 parts, Cornu Cervi Pantotrichum; Hirudo 27 parts, Herba Hedyotidis Diffusae 18 parts, Spica Prunellae 9 parts; Herba Scutellariae Barbatae 15 parts, Calculus Bovis 12 parts, Scolopendra 11 parts.
4. the pharmaceutical composition of anti-nonsmall-cell lung cancer according to claim 1, is characterized in that: raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 13 parts, Radix Pseudostellariae 17 parts, Radix Ophiopogonis 30 parts; Fructus Schisandrae Chinensis 14 parts, Cordyceps 23 parts, Radix Codonopsis 6 parts, Bulbus Fritillariae Cirrhosae 13 parts; Semen Armeniacae Amarum 6 parts, Folium Eriobotryae 9 parts, Herba Houttuyniae 11 parts; Radix Angelicae Sinensis 15 parts, Radix Notoginseng 8 parts, 19 parts, Cornu Cervi Pantotrichum; Hirudo 30 parts, Herba Hedyotidis Diffusae 13 parts, Spica Prunellae 5 parts; Herba Scutellariae Barbatae 9 parts, Calculus Bovis 10 parts, Scolopendra 12 parts.
5. the pharmaceutical composition of anti-nonsmall-cell lung cancer according to claim 1, is characterized in that: raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 8 parts, Radix Pseudostellariae 20 parts, Radix Ophiopogonis 19 parts; Fructus Schisandrae Chinensis 27 parts, Cordyceps 17 parts, Radix Codonopsis 5 parts, Bulbus Fritillariae Cirrhosae 19 parts; Semen Armeniacae Amarum 10 parts, Folium Eriobotryae 6 parts, Herba Houttuyniae 15 parts; Radix Angelicae Sinensis 14 parts, Radix Notoginseng 18 parts, 27 parts, Cornu Cervi Pantotrichum; Hirudo 32 parts, Herba Hedyotidis Diffusae 15 parts, Spica Prunellae 4 parts; Herba Scutellariae Barbatae 12 parts, Calculus Bovis 8 parts, Scolopendra 7 parts.
6. the pharmaceutical composition of anti-nonsmall-cell lung cancer according to claim 1, is characterized in that: raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 9 parts, Radix Pseudostellariae 15 parts, Radix Ophiopogonis 24 parts; Fructus Schisandrae Chinensis 16 parts, Cordyceps 19 parts, Radix Codonopsis 8 parts, Bulbus Fritillariae Cirrhosae 16 parts; Semen Armeniacae Amarum 12 parts, Folium Eriobotryae 8 parts, Herba Houttuyniae 16 parts; Radix Angelicae Sinensis 25 parts, Radix Notoginseng 15 parts, 30 parts, Cornu Cervi Pantotrichum; Hirudo 18 parts, Herba Hedyotidis Diffusae 20 parts, Spica Prunellae 7 parts; Herba Scutellariae Barbatae 14 parts, Calculus Bovis 9 parts, Scolopendra 9 parts.
7. the pharmaceutical composition of anti-nonsmall-cell lung cancer according to claim 1, is characterized in that: raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 11 parts, Radix Pseudostellariae 18 parts, Radix Ophiopogonis 28 parts; Fructus Schisandrae Chinensis 23 parts, Cordyceps 18 parts, Radix Codonopsis 9 parts, Bulbus Fritillariae Cirrhosae 17 parts; Semen Armeniacae Amarum 8 parts, Folium Eriobotryae 3 parts, Herba Houttuyniae 12 parts; Radix Angelicae Sinensis 23 parts, Radix Notoginseng 11 parts, 22 parts, Cornu Cervi Pantotrichum; Hirudo 20 parts, Herba Hedyotidis Diffusae 24 parts, Spica Prunellae 9 parts; Herba Scutellariae Barbatae 10 parts, Calculus Bovis 11 parts, Scolopendra 8 parts.
8. the pharmaceutical composition of anti-nonsmall-cell lung cancer according to claim 1, is characterized in that: raw material composition and the parts by weight of making described pharmaceutical composition are: the Radix Astragali 7 parts, Radix Pseudostellariae 16 parts, Radix Ophiopogonis 21 parts; Fructus Schisandrae Chinensis 26 parts, Cordyceps 22 parts, Radix Codonopsis 5-11 part, Bulbus Fritillariae Cirrhosae 13 parts; Semen Armeniacae Amarum 10 parts, Folium Eriobotryae 5 parts, Herba Houttuyniae 11 parts; Radix Angelicae Sinensis 20 parts, Radix Notoginseng 13 parts, 25 parts, Cornu Cervi Pantotrichum; Hirudo 25 parts, Herba Hedyotidis Diffusae 22 parts, Spica Prunellae 6 parts; Herba Scutellariae Barbatae 11 parts, Calculus Bovis 8 parts, Scolopendra 10 parts.
9. a preparation method for the pharmaceutical composition of the arbitrary described anti-nonsmall-cell lung cancer of claim 2-8, it is characterized in that, described preparation method comprises the steps:
---get each medical material by needed raw material composition and parts by weight, add the 6-8 water doubly of medical material gross weight, soak 30-60 minute, decoct 2 times, each 2-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 75% (v/v), leave standstill 30-40 hour, get supernatant, reclaim ethanol and concentrate, add water to 1000ml, stir evenly, subpackage, flowing steam sterilization 35min, obtained mixture; Or
---get each medical material by needed raw material composition and parts by weight, add the water of 10 times of medical material gross weight, soak 60-100 minute, decoct 2 times, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is the testing result under 60-65 degree Celsius, adding ethanol to alcohol content is 85% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting obtains tablet; Or
---get each medical material by needed raw material composition and parts by weight, add the 8-10 water doubly of medical material gross weight, soak 45-60 minute, decoct 4 times, each 1.5-2 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is the testing result under 60-65 degree Celsius, adding ethanol to alcohol content is 90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated obtained capsule product; Or
---get each medical material by needed raw material composition and parts by weight, add 6-10 times of water gaging, decoct 2-3 hour, leach medicine juice; Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice; Merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount ethanol, stir precipitates overnight; Get supernatant, be concentrated into thick extractum; Add pharmaceutic adjuvant, vacuum drying, pulverize and granulate, dry, granulate, obtains 20g granule, subpackage 10g/ bag, obtained granule; Or
---get each medical material by needed raw material composition and parts by weight, add 6-9 times of water gaging, decoct 2-3 hour, leach medicine juice; Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice; Merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount ethanol, stir precipitates overnight; Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, make oral liquid; Or
---get each medical material by needed raw material composition and parts by weight, add 6-9 times of water gaging, decoct 2-3 hour, leach medicine juice; Add 6-10 times of water gaging again, decoct 0.5-2 hour, leach medicine juice; Merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 times amount ethanol, stir precipitates overnight; Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, make syrup.
10. the application of pharmaceutical composition in anti-non-small cell lung cancer drug of the anti-nonsmall-cell lung cancer as described in as arbitrary in claim 1-8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410851720.9A CN104547525A (en) | 2014-12-31 | 2014-12-31 | Drug composition for NSCLC (Non Small Cell Lung Cancer) prevention and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410851720.9A CN104547525A (en) | 2014-12-31 | 2014-12-31 | Drug composition for NSCLC (Non Small Cell Lung Cancer) prevention and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104547525A true CN104547525A (en) | 2015-04-29 |
Family
ID=53065296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410851720.9A Pending CN104547525A (en) | 2014-12-31 | 2014-12-31 | Drug composition for NSCLC (Non Small Cell Lung Cancer) prevention and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547525A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213911A (en) * | 2015-10-30 | 2016-01-06 | 山东省立医院 | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma |
| WO2016197012A1 (en) * | 2015-06-03 | 2016-12-08 | Orient Pharma Inc. | Methods and compositions for treating non-small cell lung cancer |
| CN106237174A (en) * | 2016-08-31 | 2016-12-21 | 郑心 | A kind of anti-lung-cancer medicament being applicable to stagnation of QI matter and preparation method thereof |
| CN106266765A (en) * | 2016-08-31 | 2017-01-04 | 郑心 | A kind of anti-lung-cancer medicament being applicable to phlegm-damp matter and preparation method thereof |
| CN106310023A (en) * | 2016-11-10 | 2017-01-11 | 林树芳 | Drug for treating small cell lung cancer, and preparation method and application thereof |
| CN106620391A (en) * | 2017-01-10 | 2017-05-10 | 平阴县中医医院 | Medicine for treating advanced non-small-cell lung cancer and preparation method of medicine |
| CN110859917A (en) * | 2018-08-06 | 2020-03-06 | 曾令元 | Chinese herbal medicine composition for treating lung cancer and preparation method thereof |
| CN111686192A (en) * | 2019-03-15 | 2020-09-22 | 石小和 | Combination preparation for treating lung cancer and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100425978B1 (en) * | 2001-09-13 | 2004-04-06 | 조정원 | Compositions having Anti-cancer Activities |
| CN1628709A (en) * | 2003-12-18 | 2005-06-22 | 于志朋 | Method for preparing lung benefiting and obstruction dispersing liquor |
| CN102716320A (en) * | 2012-07-13 | 2012-10-10 | 杨献华 | Medicinal composition for treating non-small cell lung cancer |
-
2014
- 2014-12-31 CN CN201410851720.9A patent/CN104547525A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100425978B1 (en) * | 2001-09-13 | 2004-04-06 | 조정원 | Compositions having Anti-cancer Activities |
| CN1628709A (en) * | 2003-12-18 | 2005-06-22 | 于志朋 | Method for preparing lung benefiting and obstruction dispersing liquor |
| CN102716320A (en) * | 2012-07-13 | 2012-10-10 | 杨献华 | Medicinal composition for treating non-small cell lung cancer |
Non-Patent Citations (3)
| Title |
|---|
| 宋敬东: "《学用中药养生治病一本通》", 31 July 2014 * |
| 常青: "《中西医结合临床精萃》", 30 September 1999 * |
| 窦昌贵: "《中药学》", 31 August 2003 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016197012A1 (en) * | 2015-06-03 | 2016-12-08 | Orient Pharma Inc. | Methods and compositions for treating non-small cell lung cancer |
| US10953059B2 (en) | 2015-06-03 | 2021-03-23 | Chang Gung Medical Foundation Keelung Chang Gung Memorial Hospital | Methods and compositions for treating non-small cell lung cancer |
| CN105213911A (en) * | 2015-10-30 | 2016-01-06 | 山东省立医院 | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma |
| CN106237174A (en) * | 2016-08-31 | 2016-12-21 | 郑心 | A kind of anti-lung-cancer medicament being applicable to stagnation of QI matter and preparation method thereof |
| CN106266765A (en) * | 2016-08-31 | 2017-01-04 | 郑心 | A kind of anti-lung-cancer medicament being applicable to phlegm-damp matter and preparation method thereof |
| CN106266765B (en) * | 2016-08-31 | 2019-05-10 | 郑心 | A kind of anti-lung-cancer medicament and preparation method thereof suitable for phlegm wet matter |
| CN106310023A (en) * | 2016-11-10 | 2017-01-11 | 林树芳 | Drug for treating small cell lung cancer, and preparation method and application thereof |
| CN106620391A (en) * | 2017-01-10 | 2017-05-10 | 平阴县中医医院 | Medicine for treating advanced non-small-cell lung cancer and preparation method of medicine |
| CN106620391B (en) * | 2017-01-10 | 2019-08-09 | 平阴县中医医院 | A kind of drug and preparation method thereof for treating advanced Non-small cell lung |
| CN110859917A (en) * | 2018-08-06 | 2020-03-06 | 曾令元 | Chinese herbal medicine composition for treating lung cancer and preparation method thereof |
| CN111686192A (en) * | 2019-03-15 | 2020-09-22 | 石小和 | Combination preparation for treating lung cancer and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104547525A (en) | Drug composition for NSCLC (Non Small Cell Lung Cancer) prevention and preparation method thereof | |
| CN102580000B (en) | Medicament for curing cancer pain and preparation method thereof | |
| CN106620391B (en) | A kind of drug and preparation method thereof for treating advanced Non-small cell lung | |
| CN103520395A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN102526498A (en) | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN102716361A (en) | Blood-glucose-lowering and pancreatic-islet-recovering plaster | |
| CN105031454A (en) | Medicine for treating pulmonary tuberculosis | |
| CN103263587B (en) | Traditional Chinese medicine preparation for treating toxic and side effects of nasopharyngeal carcinoma after radiotherapy and preparation method thereof | |
| CN110339276B (en) | Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof | |
| CN102940808A (en) | Prescription medicine for treating lung cancer and preparation method | |
| CN103920114B (en) | Traditional Chinese medicinal composition for treating pulmonary fibrosis | |
| CN103735780B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of chronic bronchitis | |
| CN103417911B (en) | Traditional Chinese medicine composition for supporting chemo-treatment | |
| CN104147269A (en) | Traditional Chinese medicine used for treating systemic lupus erythematosus | |
| CN107875311A (en) | A kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer | |
| CN103285343A (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN102935214B (en) | Traditional Chinese medicinal composition for treating uremia | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN105497448A (en) | Traditional Chinese medicine preparation for treating breast cancer and preparation method thereof | |
| CN105521246A (en) | Medicinal preparation for treating lung cancer and applications of medicinal preparation | |
| CN104707126A (en) | Medicament for treating streptococcus pneumonia infected pneumonia and preparation method thereof | |
| CN104116846A (en) | Preparation method of antitumor traditional Chinese medicine composition | |
| CN109700931A (en) | A kind of drug and preparation method thereof for the concurrent celiothelioma of Chronic Obstructive Pulmonary Disease | |
| CN105194484A (en) | Chinese herb preparation for preventing and treating ovarian cancer and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150429 |